Table 2.
Clinical history of population of patients with CF
| Patient Number | Age (mo) | Sex | Genotype | Weight for Length Percentile | Dornase α | Hypertonic Saline | Prior CF Pathogens | Prior Antibiotic Courses | Prior Hospitalizations |
|---|---|---|---|---|---|---|---|---|---|
| 01 | 23 | M | F508del/F508del | 83.8 | Yes | No | SA | Oral: 5 | 2 |
| PA | Inhaled: 1 | ||||||||
| IV: 8 | |||||||||
| 02 | 24 | F | F508del/F508del | 55.5 | Yes | No | SA | Oral: 6 | 2 |
| PA | Inhaled: 1 | ||||||||
| HI | IV: 8 | ||||||||
| 03 | 40 | M | F508del/F508del | 77.6 | Yes | No | SA | Oral: 5 | 2 |
| HI | Ear drops: 1 | ||||||||
| Eye drops: 1 | |||||||||
| 04 | 37 | M | F508del/F508del | 21.4 | Yes | No | SA | None | 0 |
| HI | |||||||||
| 05 | 27 | M | F508del/R117H | 96.1 | No | No | HI | Oral: 1 | 1 |
| SP | Eye drops: 2 | ||||||||
| SM | |||||||||
| 06 | 30 | M | F508del/Q493X | 45.1 | Yes | Yes | HI | Oral: 9 | 3 |
| ORSA | Inhaled: 1 | ||||||||
| IV: 2 | |||||||||
| Eye drops: 3 | |||||||||
| 07 | 36 | F | F508del/F508del | 72.5 | Yes | No | PA | Oral: 8 | 5 |
| HI | Inhaled: 4 | ||||||||
| ORSA | IV: 3 | ||||||||
| SM | |||||||||
| 08 | 37 | F | F508del/F508del | 90.3 | No | No | PA | Oral - 1 | 0 |
| HI | Inhaled: 1 | ||||||||
| SA | |||||||||
| 09 | 33 | F | F508del/F508del | 61.4 | Yes | Yes | PA | Oral: 17 | 4 |
| HI | Inhaled: 2 | ||||||||
| ORSA | IV: 3 | ||||||||
| SM | |||||||||
| 10 | 35 | M | F508del/F508del | 31.0 | Yes | Yes | ORSA | None | 0 |
| SM | |||||||||
| 11 | 28 | M | F508del/Unknown | 80.0 | Yes | Yes | ORSA | Oral: 15 | 0 |
| HI | Inhaled: 2 | ||||||||
| IV: 4 |
Definition of abbreviations: CF = cystic fibrosis; HI = Haemophilus influenzae; ORSA = oxacillin-resistant Staphylococcus aureus; PA = Pseudomonas aeruginosa; SA = Staphylococcus aureus; SM = Stenotrophomonas maltophilia; SP = Streptococcus pyogenes (strep A).
All patients were prescribed pancreatic enzyme replacement therapy, twice daily airway clearance, and fat-soluble vitamins.